NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+25.35%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.62B
AUM Growth
+$1.62B
(+20%)
Cap. Flow
-$122M
Cap. Flow
% of AUM
-7.53%
Top 10 Holdings %
Top 10 Hldgs %
60.86%
Holding
43
New
3
Increased
6
Reduced
5
Closed
7
Top Buys
| 1 |
CRGX
CARGO Therapeutics
CRGX
|
$28.9M |
| 2 |
VERV
Verve Therapeutics
VERV
|
$27.9M |
| 3 |
Lexeo Therapeutics
LXEO
|
$17.6M |
| 4 |
4D Molecular Therapeutics
FDMT
|
$6.08M |
| 5 |
Pharvaris
PHVS
|
$5.89M |
Top Sells
| 1 |
Disc Medicine
IRON
|
$51.2M |
| 2 |
Arcellx
ACLX
|
$38.6M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$33.9M |
| 4 |
Corcept Therapeutics
CORT
|
$31.4M |
| 5 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$25.3M |
Sector Composition
| 1 | Healthcare | 52.2% |
| 2 | Technology | 25.25% |
| 3 | Financials | 11.17% |
| 4 | Industrials | 4.91% |
| 5 | Communication Services | 4.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Brookfield
BN
$98.3B
| $156M | 9.61% | 3,880,230 | – | – |
|
2
ASML
ASML
$292B
| $150M | 9.24% | 197,760 | – | – |
|
3
Salesforce
CRM
$245B
| $140M | 8.62% | 530,500 | – | – |
|
4
Spero Therapeutics
SPRO
$116M
| $123M | 7.62% | 468,902 | – | – |
|
5
LanzaTech
LNZA
$49.1M
| $79.5M | 4.91% | 15,814,845 | – | – |
|
|
6
Corcept Therapeutics
CORT
$7.35B
| $78.3M | 4.84% | 2,411,362 -966,406 | -29% | -$31.4M |
|
7
TSMC
TSM
$1.2T
| $73.9M | 4.56% | 710,780 | – | – |
|
8
Edgewise Therapeutics
EWTX
$1.51B
| $66.4M | 4.1% | 6,071,703 | – | – |
|
9
Cable One
CABO
$909M
| $65.9M | 4.07% | 118,403 | – | – |
|
10
Vaxcyte
PCVX
$4B
| $53.1M | 3.28% | 845,000 | – | – |
|
11
Mirum Pharmaceuticals
MIRM
$3.71B
| $44.3M | 2.73% | 1,500,000 | – | – |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $43.4M | 2.68% | 450,000 +50,000 | +13% | +$4.82M |
|
|
13
Pharvaris
PHVS
$1.39B
| $43.2M | 2.67% | 1,539,325 +210,000 | +16% | +$5.89M |
|
14
Apple
AAPL
$3.45T
| $42.6M | 2.63% | 221,460 | – | – |
|
15
Insmed
INSM
$28.8B
| $41.5M | 2.56% | 1,339,304 | – | – |
|
16
Crinetics Pharmaceuticals
CRNX
$2.92B
| $39.1M | 2.42% | 1,100,000 | – | – |
|
17
Alibaba
BABA
$322B
| $38.8M | 2.4% | 500,827 | – | – |
|
18
Amicus Therapeutics
FOLD
$2.34B
| $35.5M | 2.19% | 2,500,000 +404,100 | +19% | +$5.73M |
|
|
BPMC
19
DELISTED
Blueprint Medicines
BPMC
| $33.1M | 2.05% | 359,126 -165,874 | -32% | -$15.3M |
|
20
Rocket Pharmaceuticals
RCKT
$354M
| $31.5M | 1.94% | 1,050,000 +49,000 | +5% | +$1.47M |
|
|
21
4D Molecular Therapeutics
FDMT
$288M
| $30.4M | 1.88% | 1,500,000 +300,000 | +25% | +$6.08M |
|
|
CRGX
22
DELISTED
CARGO Therapeutics
CRGX
| $28.9M | 1.79% | +1,250,000 | New | +$28.9M |
|
|
VERV
23
DELISTED
Verve Therapeutics
VERV
| $27.9M | 1.72% | +2,000,000 | New | +$27.9M |
|
24
Brookfield Asset Management
BAM
$97B
| $25.2M | 1.56% | 627,207 | – | – |
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| $22.7M | 1.4% | 118,383 | – | – |
|